Thoracic Aortic Aneurysm Market By Type (Ascending Aortic Aneurysm, Descending Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, Aortic Arch Aneurysm), By Intervention Type (Stent Grafts, Surgical Grafts, Endovascular Instruments, Imaging & Diagnostic Devices, Others), By Treatment Type (Surgical Repair, Medical Management), By End-User (Hospitals, Specialty Cardiac and Vascular Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape the Thoracic Aortic Aneurysm Market in the coming years?

The Thoracic Aortic Aneurysm Market accounted for USD 1.83 Billion in 2024 and USD 2.08 Billion in 2025 is expected to reach USD 7.51Billion by 2035, growing at a CAGR of around 13.7% between 2025 and 2035. The Thoracic Aortic Aneurysm Market is dedicated to the medical equipment, diagnostic equipment, and treatment methods applied to the management of aneurysms that are located at the thoracic part of the aorta. A thoracic aortic aneurysm is a swelling or ballooning lesion of the aorta, the large blood vessel that can transfer blood out of the heart to the other parts of the body. Other complications of these aneurysms are life-threatening when the aneurysm bursts or ruptures.

The market demands improved imaging technologies at the initial stages of diagnosis that can be used by the physician to determine the size, location, and development of the aneurysm, through CT scan, MRI, and echocardiography. Therapeutic options include medical treatment to prevent further enlargement, to surgery, either open surgical repair or minimally invasive endovascular-based treatment. Important market drivers are the rising incidence of cardiovascular diseases, heightened understanding of the importance of early detection, and the rising plethora of device technologies. 

What do industry experts say about the Thoracic Aortic Aneurysm Market trends?

“As awareness around trauma and body-based healing increases, Thoracic Aortic Aneurysm is gaining momentum as a transformative approach to mental health care.”

• Dr. Bessel van der Kolk, MD, Professor of Psychiatry at Boston University School of Medicine

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Thoracic Aortic Aneurysm Market?

How is the increasing prevalence of cardiovascular diseases driving the Thoracic Aortic Aneurysm market?

The Thoracic Aortic Aneurysm Market is driven by the increasing prevalence of heart diseases (CVDs). The presence of cardiovascular diseases, including hypertension, atherosclerosis, and diseases of the heart valves, is also one of the driving forces of the thoracic aortic aneurysm development, and, therefore, more people require professional diagnosis and intervention. Due to the increase in patients with CVDs, the demand for surgical interventions and endovascular procedures that treat Thoracic Aortic Aneurysms increases, so there is a corresponding increase in the market demand for devices and stent grafts, as well as healthcare solutions.

The Centers for Disease Control and Prevention (CDC) stresses the frequent nature of heart diseases, as almost 697,000 individuals in the United States died due to heart illness in 2020. These data point to the growing number of patients who need interventions for aneurysms in the aorta in the thoracic part. Moreover, breakthroughs in imaging processes and measures, programs of early detection, and expanding general knowledge among medical professionals further add to the necessity of the Thoracic Aortic Aneurysm treatment services, stimulating the development of the market. The two factors strongly point out the need for the Thoracic Aortic Aneurysm market in combating the increasing burden of cardiovascular diseases in the world.

In what ways does the aging population contribute to the rising incidence of thoracic aortic aneurysms?

The risk of developing Thoracic Aortic Aneurysms is age-related, which makes the aging population a great force impacting the Thoracic Aortic Aneurysm Market. The walls of the aorta become weaker and tend to be less elastic as one ages, thus increasing the chances of aneurysms. Such a demographic change leads to an increased number of older patients who need surgical or endovascular treatment as a solution to the management of Thoracic Aortic Aneurysm. The American Heart Association indicates that the occurrence of aortic aneurysm drastically rises in people older than 65 years, which highlights the mitigating role of aging on aneurysm rates.

A rapidly aging population, improved life expectancy, and the need to find an effective cure to Thoracic Aortic Aneurysm will propel demand for newer types of diagnostic kits, stent grafts, and other surgical equipment that can treat Thoracic Aortic Aneurysm. Furthermore, you will find that the number of patients with large volumes in this age group is being experienced at the hospitals and specialist centres dealing with the cardiac units, thus further augmenting the market. Breakthroughs in minimally invasive procedures, enhanced post-surgical care for the aged masses, are other factors that are enhancing the uptake of Thoracic Aortic Aneurysm-based treatment solutions. In general, the ageing population will build an intensive demand, so it is one of the significant growth factors of the Thoracic Aortic Aneurysm market.

How does the high cost of surgical and endovascular interventions limit market growth?

The high cost of endovascular and surgical intervention methods is a significant obstacle to the Thoracic Aortic Aneurysm Market. Endovascular operation, open aortic repair, or thoracic endovascular aortic repair (TEVAR) is an operation that involves expensive medical equipment and stent grafts and an expert surgeon, thus further increasing the costs of treatment. Such costs have the potential to restrict access to patients, especially in developing countries or among patients who do not have sufficient health insurance coverage.

Consequently, many patients will either postpone or shun the treatment, leading to decreased volume of the procedure and growth of the market. Moreover, Thoracic Aortic Aneurysm interventions are costly, which may put a financial burden on the budget of a given hospital or reduce the capitalization of smaller facilities. This financial block hinders the infiltration of the advanced form of treatment despite the increasing clinical demand. The price is therefore another factor that will limit the large spread of the Thoracic Aortic Aneurysm market.

How can emerging markets benefit from the expansion of minimally invasive device adoption?

Emerging markets provide a major opportunity to the Thoracic Aortic Aneurysm Market with the growth in the adoption of minimally invasive devices. Surgery options such as thoracic endovascular aortic repair (TEVAR) are also becoming more popular because they pose less risk, require a shorter period to recover, and shorter hospital stays. The use of these newer technologies can enable healthcare providers in developing regions to best utilize their resources in order to maximize patient outcomes.

The growing awareness of the Thoracic Aortic Aneurysm and investments into more facilities related to the healthcare industry also help in increasing the use of minimally invasive technologies. Moreover, surgical and interventional cardiologist training programs in such markets increase the adoption of the procedures. Cost-effective and technologically advanced stent grafts promote the growth of the market. In general, the proliferation of minimally invasive devices helps new markets respond to the increasing demand for efficient, safe, and widely accessible treatment of Thoracic Aortic Aneurysms, hence, offering a promising future growth perspective to the market.

What potential does the development of next-generation stent grafts offer for the market?

The opportunity in bringing next-generation stent grafts enables the Thoracic Aortic Aneurysm Market through improving both the safety and efficacy of Thoracic Aortic Aneurysm treatments, and making the same treatments accessible to more proneonates and infants. Such novel stent grafts are expected to better fit in patient-specific aortas, minimize the risks of endoleaks, and have enhanced durability. Material and design innovations make the procedures more palatable to patients and healthcare providers by enabling the use of minimally invasive deployment, reduced recovery time, and a lack of post-operative complications.

Moreover, the stent grafts of the new generation promote the wider application of such grafts even in tricky cases, which were supposed to be impossible in the past. The ongoing studies and clinical trials in the same domain are an additional force in the market, as they provide new solutions that will answer clinical needs that previously went unmet. The implementation of these highly sophisticated devices both increases physician confidence as well as the pool of patients upon whom interventions by Thoracic Aortic Aneurysm can be performed. In general, next-generation stent grafts will be one of the drivers of growth as they create opportunities to change the outcome and market penetration worldwide.

What are the key market segments in the Thoracic Aortic Aneurysm industry?

Based on the product type, the Thoracic Aortic Aneurysm Market has been classified into Ascending Aortic Aneurysm, Descending Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, and Aortic Arch Aneurysm. The most dominant segment in the market among the various thoracic aortic aneurysms is the Ascending Aortic Aneurysm. This kind of aneurysm happens in a section of the aorta going up the heart, and therefore, it is especially important because a high likelihood of complications such as rupture or aortic dissection may take place. Proper early intervention and acts are imperative, and this has led to the need for highly developed diagnostic methods as well as treatment procedures that specifically deal with cases of ascending aneurysms.

This type of aneurysm is relatively common relative to others, and this can be attributed to age, high blood pressure, and connective disorders. The dominance of this segment has been further strengthened by the use of minimally invasive processes such as endovascular repair and the availability of special types of stent grafts. Ascending aortic aneurysm treatments have become a target area of research and development in hospitals and specialty cardiac centers, as the treatments are increasingly becoming effective.

Based on the application, the Thoracic Aortic Aneurysm Market has been classified into Stent Grafts, Surgical Grafts, Endovascular Instruments, Imaging & Diagnostic Devices, and Others. With Stent Grafts having by far the largest presence in the Thoracic Aortic Aneurysm Market, when compared to the other forms of interventions. Stent grafts may also be utilized in less invasive interventions, e.g., thoracic endovascular aortic repair (TEVAR), that have recently replaced the use of open surgery, as it is less risky and it also allows faster recovery rates. Such gadgets strengthen the weakened part of the aorta to prevent rupture and to enhance the long-term vitality of the patient.

Stent grafts occupy the market mainly due to their success in the management of both elective and emergency patients, coupled with device development that could perfectly fit in the advancement of surgery relative to the minimization of complications. The use of these devices expanded in hospitals and special cardiac centers with the advancement in the knowledge of vascular surgeons and interventional cardiologists. Sustained innovation, government approvals on new stent graft prototypes, and enhanced patient/clinician awareness have further consolidated this category as the market leader in the Thoracic Aortic Aneurysm market.

Which regions are leading the Thoracic Aortic Aneurysm Market, and why?

The North American thoracic aortic aneurysm market is a major contributor to the top aortic aneurysm market, which is fueled by the presence of high-quality healthcare infrastructure and the prevalence of cardiovascular diseases. The United States dominates the region and controls a large portion of market share due to the reasons attributed to a population that is aging, with increased awareness among the population, and the introduction of minimally invasive interventions such as thoracic endovascular aortic repair.

Canada also makes its contribution to the market, which is favored by a well-developed health system and increased health spending. Solid reimbursement systems also substantiate the dominance of the region as they offer patients greater access to sophisticated diagnostic and treatment regimes. Also, research and development activities in North America are still ongoing and continue to innovate treatment modalities and improve patient outcomes, and subsequently market opportunities.

The Asia Pacific Thoracic Aortic Aneurysm Market is shrinking at a high growth rate due to various factors like ageing of the population, increasing urbanization, and the growing incidence of cardiovascular diseases. Countries such as China, India, Japan, and South Korea are progressing greatly in the development of healthcare infrastructure, which will enhance better diagnosis and treatment of the Thoracic Aortic Aneurysm patients. The popularity of less-invasive procedures, including thoracic endovascular aortic repair (TEVAR), is growing because of the decreased recovery time and reduced risk.

Strategies being undertaken by the Government to improve accessibility and affordability of healthcare are also boosting market growth. Moreover, a large patient base and increased awareness regarding cardiovascular health are stimulating the demand for enhanced imaging and testing equipment as well as treatment devices. The emphasis placed by the region on the use of innovative medical technologies and the development of its healthcare sphere makes the Asia Pacific region one of the leaders of the global Thoracic Aortic Aneurysm market.  

What does the competitive landscape of the Thoracic Aortic Aneurysm Market look like?

The Thoracic Aortic Aneurysm Market is highly competitive with multiple key players promoting innovation in treatment methods and medical devices. Key industry players that include Medtronic, W.L. Gore and Associates, Cook Medical, Terumo Corporation, and MicroPort Scientific Corporation have been instrumental in the creation and commercialization of treatment therapies to deal with Thoracic Aortic Aneurysm. To implement superior solutions that can advance patient outcomes and meet the complexity of the thoracic aortic aneurysm, these organizations spend a fortune on research and development.

New firms as well as local manufacturers are also venturing into the market, which brings about new products and models that look to create an avenue of dynamic and competitive business practices. The strategic alliances, collaborations, and partnerships among these companies can speed up the research on new treatment regimens and exchange knowledge. The competitors have plans to improve their product lines, penetrate new geographical markets, and attain regulatory endorsements of sophisticated devices. Focusing on technological innovations, clinical efficacy, and patient-focused solutions, these firms are going to achieve their mission to enhance their role in the global Thoracic Aortic Aneurysm market.

Which recent mergers, acquisitions, or product launches are shaping the Thoracic Aortic Aneurysm industry?

• In April 2025, Gore & Associates received FDA approval for four new large-diameter tapered sizes of its Gore TAG Conformable Thoracic Stent Graft with Active Control system. These expanded sizing options are designed to better suit varied aortic anatomies, particularly in patients with limited true lumen dimensions.
• In March 2025, Cook Medical announced the U.S. commercial launch of its Zenith Alpha 2 (ZTA2) thoracic endovascular graft following FDA approval. The device features the option for carbon dioxide flushing to reduce the risk of air embolism and is built on the company’s established Zenith platform.

Report Coverage:

By Type

• Ascending Aortic Aneurysm
• Descending Aortic Aneurysm
• Thoracoabdominal Aortic Aneurysm
• Aortic Arch Aneurysm

By Intervention Type

• Stent Grafts
• Surgical Grafts
• Endovascular Instruments
• Imaging & Diagnostic Devices
• Others

By Treatment Type

• Surgical Repair
• Medical Management

By End-User

• Hospitals
• Specialty Cardiac and Vascular Clinics
• Ambulatory Surgical Centers
• Diagnostic Centers
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Medtronic plc
• W.L. Gore & Associates, Inc.
• Cook Medical Inc.
• Terumo Corporation
• MicroPort Scientific Corporation
• Boston Scientific Corporation
• Artivion Inc.
• Cardiatis S.A.
• Endologix Inc.
• Braile Biomédica
• Lombard Medical
• CryoLife, Inc.
• JOTEC GmbH
• LifeTech Scientific Corporation
• B. Braun Melsungen AG

Frequently Asked Questions (FAQs)